Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
BACKGROUND
Salivary ductal carcinoma (SDC) is an uncommon malignant tumor of the salivary glands. Although there is no known standard of care for the treatment of advanced disease, the vast majority of patients with SDC may be offered palliative systemic therapy. We report a case of epidermal growth factor receptor 2 (HER2)-positive metastatic submandibular SDC with a complete and durable clinical response to treatment with trastuzumab in combination with chemotherapy.


RESULTS
A 62-year-old man was diagnosed with SDC of the left submandibular gland with extensive cervical lymph node involvement. The lesion was completely resected, and the patient underwent postoperative radiotherapy. After 6 months, multiple pulmonary metastatic lesions were detected. A complete response was reached with trastuzumab-based combination therapy, and no evidence of disease progression has been observed after 14 months of initiation of systemic therapy.


CONCLUSIONS
Trastuzumab-based combination therapies should be considered for advanced SDC.
Prat
Aleix
A
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. prat.aleix@terra.es
Parera
Marta
M
Reyes
Vicky
V
Peralta
Sergio
S
Cedrés
Susana
S
Andreu
Jordi
J
Huguet
Pere
P
del Campo
Josep Maria
JM
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D044584:Carcinoma, Ductal / Q000378:metabolism / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012468:Salivary Gland Neoplasms / Q000378:metabolism / Q000556:secondary / Q000628:therapy*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab